AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

AbbVie Inc.NYSE: ABBV

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense grows, but more slowly than its trailing trend

Q3 FY2026 income tax expense of $609M rose 15.8% year over year, behind the +435.5% change in trailing-twelve-month income tax expense. Sequentially, it fell 8.0% from the prior quarter. Over 3 fiscal years it compounded at +13.1% a year.

Context

  • Income tax expense amounted to 3.9% of revenue in FY2025, up 2.9 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +15.8% toward the trailing-twelve-month pace of +435.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$609M-8.0% QoQ
Last fiscal yearDec 2025
$2.36B+514.7% YoY
LTMSep 2026
$2.47B+435.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.8%——
1 year+514.7%——
3-year CAGR+13.1%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
2.36B USD
Year-over-year change
+514.7%
4-year CAGR
+13.2%

Income Tax Expense vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +435.5% is the highest of 10, against a peer median of +29.9%.
  • Income tax expense amounts to 3.7% of revenue for ABBV, versus a peer median of 4.0%.
ABBV Competitors
Income Tax Expense for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$6.88B USD+125.0%+108.5%8.6%
MRKMerck & Co., Inc.LTM Jun 2026$2.78B USD+1.3%+13.5%4.2%
NVSNovartis AGLTM Jun 2026$2.78B USD+40.9%+28.6%5.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$2.63B USD+72.3%+18.4%5.4%
ABBVAbbVie Inc.LTM Sep 2026$2.47B USD+435.5%+13.1%3.7%
AZNAstraZeneca PLCLTM Sep 2026$2.25B USD+10.8%—3.6%
JNJJohnson & JohnsonLTM Sep 2026$1.64B USD-74.3%+24.6%1.7%
AMGNAmgen Inc.LTM Jun 2026$1.54B USD+91.8%+16.8%4.0%
GSKGSK plcLTM Jun 2026£641M GBP+0.5%+16.3%1.9%
PFEPfizer Inc.LTM Jun 2026-$164M USD+29.9%—0.3%
Peer median (excluding ABBV) —+29.9%+18.4%4.0%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.2B58.05B54.32B56.33B61.16B
Cost of Revenue17.45B17.41B20.42B16.9B18.2B
Gross Profit38.75B40.64B33.9B39.43B42.96B
Gross Margin69.0%70.0%62.4%70.0%70.2%
Research & Development8.05B6.51B7.68B12.79B9.1B
Selling, General & Admin12.35B15.26B12.87B14.75B14.01B
Operating Expenses20.83B22.52B21.15B30.29B22.87B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
EBITDA23.93B24.17B17.17B14.91B17.63B
EBITDA Margin42.6%41.6%31.6%26.5%28.8%
Operating Income17.92B18.12B12.76B9.14B20.09B
Operating Margin31.9%31.2%23.5%16.2%32.8%
Interest Income39M186M540M648M266M
Interest Expense2.42B2.23B2.22B2.81B2.89B
Other Income / Expenses(4.94B)(4.64B)(6.51B)(5.42B)(13.49B)
Income Before Tax12.99B13.48B6.25B3.72B6.6B
Pre-Tax Margin23.1%23.2%11.5%6.6%10.8%
Income Tax Expense1.44B1.63B1.38B(570M)2.36B
Net Income11.54B11.84B4.86B4.28B4.23B
Net Margin20.5%20.4%9.0%7.6%6.9%
EPS (Basic)6.486.652.732.402.37
EPS (Diluted)6.456.632.722.392.37
Weighted Avg Shares1.77B1.77B1.77B1.77B1.77B
Weighted Avg Shares (Diluted)1.78B1.78B1.77B1.77B1.77B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.